Caseware UK (AP4) 2024.0.164 2024.0.164 30072386082025-01-01falsefalsefalseNo description of principal activity6470false 06000685 2025-01-01 2025-12-31 06000685 2024-01-01 2024-12-31 06000685 2025-12-31 06000685 2024-12-31 06000685 2024-01-01 06000685 1 2025-01-01 2025-12-31 06000685 1 2024-01-01 2024-12-31 06000685 2 2025-01-01 2025-12-31 06000685 2 2024-01-01 2024-12-31 06000685 5 2025-01-01 2025-12-31 06000685 5 2024-01-01 2024-12-31 06000685 d:Exceptional 2025-01-01 2025-12-31 06000685 d:Exceptional 2024-01-01 2024-12-31 06000685 e:Director1 2025-01-01 2025-12-31 06000685 e:Director3 2025-01-01 2025-12-31 06000685 e:Director5 2025-01-01 2025-12-31 06000685 e:Director5 2025-12-31 06000685 e:Director6 2025-01-01 2025-12-31 06000685 e:Director6 2025-12-31 06000685 e:Director7 2025-01-01 2025-12-31 06000685 e:Director7 2025-12-31 06000685 e:Director8 2025-01-01 2025-12-31 06000685 e:Director10 2025-01-01 2025-12-31 06000685 e:Director10 2025-12-31 06000685 e:RegisteredOffice 2025-01-01 2025-12-31 06000685 e:Agent1 2025-01-01 2025-12-31 06000685 d:Buildings 2025-01-01 2025-12-31 06000685 d:Buildings 2025-12-31 06000685 d:Buildings 2024-12-31 06000685 d:Buildings d:OwnedOrFreeholdAssets 2025-01-01 2025-12-31 06000685 d:PlantMachinery 2025-01-01 2025-12-31 06000685 d:PlantMachinery 2025-12-31 06000685 d:PlantMachinery 2024-12-31 06000685 d:PlantMachinery d:OwnedOrFreeholdAssets 2025-01-01 2025-12-31 06000685 d:OtherPropertyPlantEquipment 2025-01-01 2025-12-31 06000685 d:OwnedOrFreeholdAssets 2025-01-01 2025-12-31 06000685 d:CurrentFinancialInstruments 2025-12-31 06000685 d:CurrentFinancialInstruments 2024-12-31 06000685 d:CurrentFinancialInstruments 3 2025-12-31 06000685 d:CurrentFinancialInstruments 3 2024-12-31 06000685 d:Non-currentFinancialInstruments 2025-12-31 06000685 d:Non-currentFinancialInstruments 2024-12-31 06000685 d:CurrentFinancialInstruments d:WithinOneYear 2025-12-31 06000685 d:CurrentFinancialInstruments d:WithinOneYear 2024-12-31 06000685 d:Non-currentFinancialInstruments d:AfterOneYear 2025-12-31 06000685 d:Non-currentFinancialInstruments d:AfterOneYear 2024-12-31 06000685 d:Non-currentFinancialInstruments d:BetweenOneTwoYears 2025-12-31 06000685 d:Non-currentFinancialInstruments d:BetweenOneTwoYears 2024-12-31 06000685 d:Non-currentFinancialInstruments d:BetweenTwoFiveYears 2025-12-31 06000685 d:Non-currentFinancialInstruments d:BetweenTwoFiveYears 2024-12-31 06000685 d:Non-currentFinancialInstruments d:MoreThanFiveYears 2025-12-31 06000685 d:Non-currentFinancialInstruments d:MoreThanFiveYears 2024-12-31 06000685 d:ReportableOperatingSegment1 2025-01-01 2025-12-31 06000685 d:ReportableOperatingSegment1 2024-01-01 2024-12-31 06000685 d:UKTax 2025-01-01 2025-12-31 06000685 d:UKTax 2024-01-01 2024-12-31 06000685 d:ShareCapital 2025-01-01 2025-12-31 06000685 d:ShareCapital 2025-12-31 06000685 d:ShareCapital 2024-01-01 2024-12-31 06000685 d:ShareCapital 2024-12-31 06000685 d:ShareCapital 2024-01-01 06000685 d:RevaluationReserve 2025-01-01 2025-12-31 06000685 d:RevaluationReserve 2025-12-31 06000685 d:RevaluationReserve 1 2025-01-01 2025-12-31 06000685 d:RevaluationReserve 2 2025-01-01 2025-12-31 06000685 d:RevaluationReserve 2024-01-01 2024-12-31 06000685 d:RevaluationReserve 2024-12-31 06000685 d:RevaluationReserve 2024-01-01 06000685 d:RevaluationReserve 1 2024-01-01 2024-12-31 06000685 d:RevaluationReserve 2 2024-01-01 2024-12-31 06000685 d:OtherMiscellaneousReserve 2025-01-01 2025-12-31 06000685 d:OtherMiscellaneousReserve 2025-12-31 06000685 d:OtherMiscellaneousReserve 1 2025-01-01 2025-12-31 06000685 d:OtherMiscellaneousReserve 2 2025-01-01 2025-12-31 06000685 d:OtherMiscellaneousReserve 2024-01-01 2024-12-31 06000685 d:OtherMiscellaneousReserve 2024-12-31 06000685 d:OtherMiscellaneousReserve 2024-01-01 06000685 d:OtherMiscellaneousReserve 1 2024-01-01 2024-12-31 06000685 d:OtherMiscellaneousReserve 2 2024-01-01 2024-12-31 06000685 d:RetainedEarningsAccumulatedLosses 2025-01-01 2025-12-31 06000685 d:RetainedEarningsAccumulatedLosses 2025-12-31 06000685 d:RetainedEarningsAccumulatedLosses 2 2025-01-01 2025-12-31 06000685 d:RetainedEarningsAccumulatedLosses 2024-01-01 2024-12-31 06000685 d:RetainedEarningsAccumulatedLosses 2024-12-31 06000685 d:RetainedEarningsAccumulatedLosses 2024-01-01 06000685 d:RetainedEarningsAccumulatedLosses 2 2024-01-01 2024-12-31 06000685 d:AcceleratedTaxDepreciationDeferredTax 2025-12-31 06000685 d:AcceleratedTaxDepreciationDeferredTax 2024-12-31 06000685 d:OtherDeferredTax 2025-12-31 06000685 d:OtherDeferredTax 2024-12-31 06000685 e:OrdinaryShareClass1 2025-01-01 2025-12-31 06000685 e:OrdinaryShareClass1 2025-12-31 06000685 e:OrdinaryShareClass1 2024-12-31 06000685 e:OrdinaryShareClass2 2025-01-01 2025-12-31 06000685 e:OrdinaryShareClass2 2025-12-31 06000685 e:OrdinaryShareClass2 2024-12-31 06000685 e:OrdinaryShareClass3 2025-01-01 2025-12-31 06000685 e:OrdinaryShareClass3 2025-12-31 06000685 e:OrdinaryShareClass3 2024-12-31 06000685 e:OrdinaryShareClass4 2025-01-01 2025-12-31 06000685 e:OrdinaryShareClass4 2025-12-31 06000685 e:OrdinaryShareClass4 2024-12-31 06000685 e:OrdinaryShareClass5 2025-01-01 2025-12-31 06000685 e:OrdinaryShareClass5 2025-12-31 06000685 e:OrdinaryShareClass5 2024-12-31 06000685 e:FRS102 2025-01-01 2025-12-31 06000685 e:Audited 2025-01-01 2025-12-31 06000685 e:FullAccounts 2025-01-01 2025-12-31 06000685 e:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 06000685 d:WithinOneYear 2025-12-31 06000685 d:WithinOneYear 2024-12-31 06000685 d:BetweenOneFiveYears 2025-12-31 06000685 d:BetweenOneFiveYears 2024-12-31 06000685 d:PlantEquipmentOtherAssetsUnderOperatingLeases 2025-12-31 06000685 d:PlantEquipmentOtherAssetsUnderOperatingLeases 2024-12-31 06000685 d:PlantEquipmentOtherAssetsUnderOperatingLeases d:WithinOneYear 2025-12-31 06000685 d:PlantEquipmentOtherAssetsUnderOperatingLeases d:WithinOneYear 2024-12-31 06000685 d:PlantEquipmentOtherAssetsUnderOperatingLeases d:BetweenOneFiveYears 2025-12-31 06000685 d:PlantEquipmentOtherAssetsUnderOperatingLeases d:BetweenOneFiveYears 2024-12-31 06000685 d:HirePurchaseContracts d:WithinOneYear 2025-12-31 06000685 d:HirePurchaseContracts d:WithinOneYear 2024-12-31 06000685 d:HirePurchaseContracts d:BetweenOneFiveYears 2025-12-31 06000685 d:HirePurchaseContracts d:BetweenOneFiveYears 2024-12-31 06000685 2 2025-01-01 2025-12-31 06000685 5 2025-01-01 2025-12-31 06000685 14 2025-01-01 2025-12-31 06000685 d:ShareCapital 2 2025-01-01 2025-12-31 06000685 d:ShareCapital 2 2024-01-01 2024-12-31 06000685 f:PoundSterling 2025-01-01 2025-12-31 iso4217:GBP xbrli:shares xbrli:pure

Registered number: 06000685









Medlock FRB Limited









Annual Report and Financial Statements

For the year ended 31 December 2025

 
Medlock FRB Limited
 
 
Company Information


Directors
C Drury 
M Peden 
D McGuire 
W Earl (appointed 14 April 2025)




Registered number
06000685



Registered office
Medlock FRB Limited
Greengate Street

Oldham

OL4 1DG




Independent auditors
Hurst Accountants Limited
Chartered Accountants & Statutory Auditors

3 Stockport Exchange

Stockport

Cheshire

SK1 3GG




Solicitors
Gateley LLP
98 King Street

Manchester

M2 4WU





 
Medlock FRB Limited
 

Contents



Page
Strategic report
 
1 - 2
Directors' report
 
3 - 4
Independent auditors' report
 
5 - 8
Statement of comprehensive income
 
9
Statement of financial position
 
10
Statement of changes in equity
 
11
Statement of cash flows
 
12
Analysis of net debt
 
13
Notes to the financial statements
 
14 - 29

 
Medlock FRB Limited
 
 
Strategic Report
For the year ended 31 December 2025

Introduction
 
The directors are pleased to present the Strategic Report for the year ended 31 December 2025.

Business review
 
The principal activity of the business remains that of a leading specialist fit-out contractor operating within the leisure and hospitality sector, and the directors do not expect this to change.

The results reflect a challenging trading year in 2025. The increase in Employer’s National Insurance to 15%, together with other regulatory pressures and worldwide events, affected the business and placed additional pressure on margins. Core material prices continued to rise during the year and, although they stabilised towards the year end, they continued to affect project costs. The business also delivered its largest project to date against a backdrop of wider market uncertainty and significant project delivery challenges.

Customer confidence also remained under pressure, driven by high borrowing costs and limited support for the sector in which the business operates. Despite these headwinds, the business generated a satisfactory profit and increased its balance sheet again. Cash generation from our projects remained strong and was aligned with controlled overhead and fixed cost expenditure.

The Board also made the decision to reward all employees with a bonus aligned with our commitment to Employee Ownership. The Board remains strongly committed to Employee Ownership and recognises that the Company cannot achieve its vision without its people being fully engaged and invested in its success.

The key focus for 2026 will remain the successful delivery of projects on time, on budget, to the highest quality standards and safely. This focus supports the Company’s vision: to deliver the best projects by the best people. We will also continue our strategy of building a world-class culture.

The Company will continue to invest significantly in its people through a structured training and development plan, and the Board remains committed to Continual Professional Development, enabling employees to achieve their full potential while supporting retention as a key part of our people strategy.

The Board of Directors extends its sincere gratitude to everyone across the Company, including employees, advisers and supply chain partners. Their professionalism and commitment remain essential to our continued growth and success.

Principal risks and uncertainties
 
Failure to deliver projects in line with customer’s expectations and required specifications, on time and on budget and to minimise the risk of increased costs and delay related damages. The risk is mitigated with continual assessment and development of key staff within our Pre-Construction, Project Delivery and Commercial teams and our Leadership team.

Supply Chain Partners fail to meet our operational and Commercial expectations and requirements in relation to capacity, competency, quality, financial stability, safety, environmental, social and ethical values. The Company has undertaken significant work to identify and understand who its key supply chain partners are and have reduced the number whilst initiating a core partnership. In addition to this we have introduced KPIs across all partnerships.

The Company has implemented policies and procedures that require appropriate credit checks on potential customers before projects are commenced, and concentration of credit risk is constantly under review.

In addition, the directors also consider that market risk is a key risk to the business.

Page 1

 
Medlock FRB Limited
 

Strategic Report (continued)
For the year ended 31 December 2025

Financial key performance indicators
 
The key financial performance indicators for the past three years are as follows:



2025
2024
2023






Turnover £'000
40,590
45,756
40,911

Gross profit £'000
3,823
4,301
3,771

Gross profit %
9%
9%
9%

EBITDA £'000
318
793
523

Operating profit £'000
268
738
468

Employee numbers
64
70
63

Turnover/employees £'000
634
654
649


This report was approved by the board and signed on its behalf.



C Drury
Director

Date: 16 September 2026
Page 2

 
Medlock FRB Limited
 
 
 
Directors' Report
For the year ended 31 December 2025

The directors present their report and the financial statements for the year ended 31 December 2025.

Directors' responsibilities statement

The directors are responsible for preparing the strategic report, the directors' report and the financial statements in accordance with applicable law and regulations.
 
Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including Financial Reporting Standard 102 ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland'. Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of the profit or loss of the Company for that period.

 In preparing these financial statements, the directors are required to:


∙select suitable accounting policies for the Company's financial statements and then apply them consistently;

∙make judgments and accounting estimates that are reasonable and prudent;

∙prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Results and dividends

The profit for the year, after taxation, amounted to £474,755 (2024 -£710,877).

Dividends of £Nil (2024: £Nil) were paid during the year. 

The directors do not recommend payment of a final dividend. 

Directors

The directors who served during the year were:

C Drury 
M Peden 
N Corfield (resigned 28 February 2025)
J Harrison (resigned 23 December 2025)
C Thornborrow-Jones (resigned 30 June 2026)
D McGuire 
W Earl (appointed 14 April 2025)

Research and development activities

The Company continues to develop new systems and processes which are aimed at improving quality and efficiency. 

Page 3

 
Medlock FRB Limited
 
 
 
Directors' Report (continued)
For the year ended 31 December 2025

Disclosure of information to auditors

Each of the persons who are directors at the time when this directors' report is approved has confirmed that:
 
∙so far as the director is aware, there is no relevant audit information of which the Company's auditors are unaware, and

∙the director has taken all the steps that ought to have been taken as a director in order to be aware of any relevant audit information and to establish that the Company's auditors are aware of that information.

Auditors

The auditors, Hurst Accountants Limited, will be proposed for reappointment in accordance with section 485 of the Companies Act 2006.

This report was approved by the board and signed on its behalf.
 



C Drury
Director

Date: 16 September 2026
Page 4

 
Medlock FRB Limited
 
 
 
Independent Auditors' Report to the Members of Medlock FRB Limited
 

Opinion


We have audited the financial statements of Medlock FRB Limited (the 'Company') for the year ended 31 December 2025, which comprise the statement of comprehensive income, the analysis of net debt, the statement of financial position, the statement of cash flows, the statement of changes in equity and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).


In our opinion the financial statements:


∙give a true and fair view of the state of the Company's affairs as at 31 December 2025 and of its profit for the year then ended;
∙have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
∙have been prepared in accordance with the requirements of the Companies Act 2006.


Basis for opinion


We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the Company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the United Kingdom, including the Financial Reporting Council's Ethical Standard and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.


Conclusions relating to going concern


In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.


Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.


Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.


Other information


The other information comprises the information included in the Annual Report other than the financial statements and our auditors' report thereon. The directors are responsible for the other information contained within the Annual Report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.


We have nothing to report in this regard.


Page 5

 
Medlock FRB Limited
 
 
 
Independent Auditors' Report to the Members of Medlock FRB Limited (continued)


Opinion on other matters prescribed by the Companies Act 2006
 

In our opinion, based on the work undertaken in the course of the audit:


∙the information given in the strategic report and the directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
∙the strategic report and the directors' report have been prepared in accordance with applicable legal requirements.


Matters on which we are required to report by exception
 

In the light of the knowledge and understanding of the Company and its environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or the directors' report.


We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:


∙adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
∙the financial statements are not in agreement with the accounting records and returns; or
∙certain disclosures of directors' remuneration specified by law are not made; or
∙we have not received all the information and explanations we require for our audit.


Responsibilities of directors
 

As explained more fully in the directors' responsibilities statement set out on page 3, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.


In preparing the financial statements, the directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Company or to cease operations, or have no realistic alternative but to do so.


Page 6

 
Medlock FRB Limited
 
 
 
Independent Auditors' Report to the Members of Medlock FRB Limited (continued)


Auditors' responsibilities for the audit of the financial statements
 


Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Identifying and assessing potential risks related to irregularities
 
In identifying and assessing the risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, we considered the following:
 
∙The nature of the industry and sector in which the company operates; the control environment and business performance including key drivers for directors' remuneration, bonus levels and performance targets.
∙The outcome of enquiries of management, including whether management was aware of any instances of non-compliance with laws and regulations, and whether management had knowledge of any actual, suspected, or alleged fraud. 
∙Supporting documentation relating to the Company's policies and procedures for:
♦Identifying, evaluating, and complying with laws and regulations
♦Detecting and responding to the risks of fraud
∙The internal controls established to mitigate risks related to fraud or non-compliance with laws and regulations.
∙The outcome of discussions amongst the engagement team regarding how and where fraud might occur in the financial statements and any potential indicators of fraud.
∙The legal and regulatory framework in which the Company operates, particularly those laws and regulations which have a direct effect on the financial statements, such as the Companies Act 2006, pensions and tax legislation, or which had a fundamental effect on the operations of the Company, including General Data Protection requirements, and Anti-bribery and Corruption.
 
Audit response to risks identified
 
Our procedures to respond to the risks identified included the following:
 
∙Reviewing the financial statements disclosures and testing to supporting documentation to assess compliance with the provisions of those relevant laws and regulations which have a direct effect on the financial statements.
∙Discussions with management, including consideration of known or suspected instances of non-compliance with laws and regulations and fraud.
∙Evaluation of management’s controls designed to prevent and detect irregularities.
∙Enquiring of management about any actual and potential litigation and claims.
∙Performing analytical procedures to identify any unusual or unexpected relationships which may indicate risks of material misstatement due to fraud.
 
Page 7

 
Medlock FRB Limited
 
 
 
Independent Auditors' Report to the Members of Medlock FRB Limited (continued)


We have also considered the risk of fraud through management override of controls by:
 
∙Testing the appropriateness of journal entries and other adjustments. We have used data analytics software to identify accounting transactions which may pose a heightened risk of material misstatement, whether due to fraud or error.
∙Challenging assumptions made by management in their significant accounting estimates, and assessing whether the judgements made in making accounting estimates are indicative of a potential bias; and
∙Evaluating the business rationale of any significant transactions that are unusual or outside the normal course of business.
 
We also communicated relevant identified laws and regulations and potential fraud risks to all engagement team members and remained alert to any indications of fraud or non-compliance with laws and regulations throughout the audit.
 
There are inherent limitations in the audit procedures described above, and the further removed non-compliance with laws and regulations are from the events and transactions reflected in the financial statements, the less likely we would become aware of them.  Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion.


A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditors' report.


Use of our report
 

This report is made solely to the Company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Company's members those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company's members, as a body, for our audit work, for this report, or for the opinions we have formed.



Chris Stewardson (senior statutory auditor)
for and on behalf of
Hurst Accountants Limited
Chartered Accountants
Statutory Auditors
3 Stockport Exchange
Stockport
Cheshire
SK1 3GG

17 September 2026
Page 8

 
Medlock FRB Limited
 
 
Statement of Comprehensive Income
For the year ended 31 December 2025

2025
2024
Note
£
£

  

Turnover
 4 
40,590,009
45,756,144

Cost of sales
  
(36,767,062)
(41,455,325)

Gross profit
  
3,822,947
4,300,819

Administrative expenses
  
(3,792,110)
(3,440,833)

Other operating income
 5 
544,192
100,000

Discretionary Staff Bonus – Including EOT Bonuses
  
(307,344)
(222,180)

Operating profit
 6 
267,685
737,806

Interest receivable and similar income
 10 
555
-

Interest payable and similar expenses
 11 
(30,072)
(38,608)

Profit before tax
  
238,168
699,198

Tax on profit
 12 
236,587
11,679

Profit for the financial year
  
474,755
710,877

There was no other comprehensive income for 2025 (2024:£NIL).

The notes on pages 14 to 29 form part of these financial statements.
Page 9

 
Medlock FRB Limited
Registered number: 06000685

Statement of Financial Position
As at 31 December 2025

2025
2024
Note
£
£

Fixed assets
  

Tangible assets
 13 
938,088
972,501

Current assets
  

Debtors: amounts falling due within one year
 14 
7,436,247
9,358,242

Cash at bank and in hand
 15 
3,093,222
1,495,739

  
10,529,469
10,853,981

Creditors: amounts falling due within one year
 16 
(8,705,988)
(9,095,421)

Net current assets
  
 
 
1,823,481
 
 
1,758,560

Total assets less current liabilities
  
2,761,569
2,731,061

Creditors: amounts falling due after more than one year
 17 
(313,434)
(382,347)

Provisions for liabilities
  

Deferred tax
 20 
(14,183)
(24,716)

Net assets
  
2,433,952
2,323,998


Capital and reserves
  

Called up share capital 
 21 
22,225
22,225

Revaluation reserve
 22 
484,000
494,000

Other reserves
 22 
(2,962,254)
(2,597,453)

Profit and loss account
 22 
4,889,981
4,405,226

  
2,433,952
2,323,998


The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




C Drury
Director

Date: 16 September 2026

The notes on pages 14 to 29 form part of these financial statements.
Page 10

 
Medlock FRB Limited
 

Statement of Changes in Equity
For the year ended 31 December 2025


Called up share capital
Revaluation reserve
Other reserves
Profit and loss account
Total equity

£
£
£
£
£

At 1 January 2025
22,225
494,000
(2,597,453)
4,405,226
2,323,998


Comprehensive income for the year

Profit for the year
-
-
-
474,755
474,755
Total comprehensive income for the year
-
-
-
474,755
474,755


Contributions by and distributions to owners

Transfer from revaluation reserve
-
-
-
10,000
10,000

Transfer to profit and loss account
-
(10,000)
-
-
(10,000)

Contribution to employee ownership trust
-
-
(364,801)
-
(364,801)


Total transactions with owners
-
(10,000)
(364,801)
10,000
(364,801)


At 31 December 2025
22,225
484,000
(2,962,254)
4,889,981
2,433,952



Statement of Changes in Equity
For the year ended 31 December 2024


Called up share capital
Revaluation reserve
Other reserves
Profit and loss account
Total equity

£
£
£
£
£

At 1 January 2024
22,225
504,000
(1,965,000)
3,684,349
2,245,574


Comprehensive income for the year

Profit for the year
-
-
-
710,877
710,877
Total comprehensive income for the year
-
-
-
710,877
710,877


Contributions by and distributions to owners

Transfer from revaluation reserve
-
-
-
10,000
10,000

Transfer to profit and loss account
-
(10,000)
-
-
(10,000)

Contribution to employee ownership trust
-
-
(632,453)
-
(632,453)


Total transactions with owners
-
(10,000)
(632,453)
10,000
(632,453)


At 31 December 2024
22,225
494,000
(2,597,453)
4,405,226
2,323,998


The notes on pages 14 to 29 form part of these financial statements.
Page 11

 
Medlock FRB Limited
 

Statement of Cash Flows
For the year ended 31 December 2025

2025
2024
£
£

Cash flows from operating activities

Profit for the financial year
474,755
710,877

Adjustments for:

Depreciation of tangible assets
50,568
54,918

Government grants
(552,932)
-

Interest paid
30,072
38,608

Interest received
(555)
-

Taxation charge
(236,587)
(11,679)

Decrease/(increase) in debtors
1,828,801
(1,282,579)

Decrease/(increase) in amounts owed by related parties
507,893
(324,054)

(Decrease)/increase in creditors
(199,713)
1,051,981

Corporation tax received
170,509
103,952

Net cash generated from operating activities

2,072,811
342,024


Cash flows from investing activities

Purchase of tangible fixed assets
(16,155)
(47,478)

Interest received
555
-

Net cash from investing activities

(15,600)
(47,478)

Cash flows from financing activities

Repayment of loans
(55,855)
(42,389)

Repayment of hire purchase contracts
(9,000)
(9,000)

Interest paid
(27,464)
(36,000)

HP interest paid
(2,608)
(2,608)

Contributions to employee ownership trust
(364,801)
(632,453)

Net cash used in financing activities
(459,728)
(722,450)

Net increase/(decrease) in cash and cash equivalents
1,597,483
(427,904)

Cash and cash equivalents at beginning of year
1,495,739
1,923,643

Cash and cash equivalents at the end of year
3,093,222
1,495,739


Cash and cash equivalents at the end of year comprise:

Cash at bank and in hand
3,093,222
1,495,739


The notes on pages 14 to 29 form part of these financial statements.

Page 12

 
Medlock FRB Limited
 

Analysis of Net Debt
For the year ended 31 December 2025





At 1 January 2025
Cash flows
Other non-cash changes
At 31 December 2025
£

£

£

£

Cash at bank and in hand

1,495,739

1,597,483

-

3,093,222

Debt due after 1 year

(356,828)

-

59,006

(297,822)

Debt due within 1 year

(53,964)

55,855

(59,006)

(57,115)

Hire purchase contracts

(33,750)

9,000

-

(24,750)


1,051,197
1,662,338
-
2,713,535

The notes on pages 14 to 29 form part of these financial statements.
Page 13

 
Medlock FRB Limited
 
 
 
Notes to the Financial Statements
For the year ended 31 December 2025

1.


General information

Medlock FRB Limited is a private company limited by shares and incorporated in England and Wales. The address of the registered office and principal place of business is Greengate Street, Oldham, Lancashire, OL4 1DG. The company's registered number is 06000685. 

The nature of the Company's operations and its principal activity is that of construction and refurbishment contracts. 

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies (see note 3).

The following principal accounting policies have been applied:

 
2.2

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Construction contracts

Revenue from a contract to provide construction services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:

∙the amount of revenue can be measured reliably;
∙it is probable that the company will receive the consideration due under the contract;
∙the stage of completion of the contract at the end of the reporting period can be measured reliably, and;
∙the costs incurred and the costs to complete the contract can be measured reliably.

Profit on long-term contracts is taken as the work is carried out if the final outcome can be assessed with reasonable certainty. The profit included is calculated on a prudent basis to reflect the proportion of the work carried out at the year end, by recording turnover and related costs as contract activity progresses. Revenue is calculated as that proportion of total contract value which costs incurred to date bear to total expected costs for that contract. Full provision is made for losses on all contracts in the year in which they are first foreseen.

Amounts recoverable on contracts are included in current assets and represent revenue recognised in excess of payments on account.

 
2.3

Operating leases: the Company as lessee

Rentals paid under operating leases are charged to profit or loss on a straight-line basis over the lease term.

Page 14

 
Medlock FRB Limited
 
 
 
Notes to the Financial Statements
For the year ended 31 December 2025

2.Accounting policies (continued)

 
2.4

Government grants

Grants of a revenue nature are recognised in the statement of comprehensive income in the same period as the related expenditure.

 
2.5

Interest income

Interest income is recognised in profit or loss using the effective interest method.

 
2.6

Finance costs

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. 

 
2.7

Borrowing costs

All borrowing costs are recognised in profit or loss in the year in which they are incurred.

 
2.8

Pensions

Defined contribution pension plan

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the statement of financial position. The assets of the plan are held separately from the Company in independently administered funds.

Page 15

 
Medlock FRB Limited
 
 
 
Notes to the Financial Statements
For the year ended 31 December 2025

2.Accounting policies (continued)

 
2.9

Current and deferred taxation

The tax expense for the year comprises current and deferred tax. Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the reporting date, except that:
∙The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
∙Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.


 
2.10

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Freehold property
-
50 years
Plant and machinery
-
5 - 10 years

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

Page 16

 
Medlock FRB Limited
 
 
 
Notes to the Financial Statements
For the year ended 31 December 2025

2.Accounting policies (continued)

 
2.11

Revaluation of tangible fixed assets

Individual freehold and leasehold properties are carried at current year value at fair value at the date of the revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses. Revaluations are undertaken with sufficient regularity to ensure the carrying amount does not differ materially from that which would be determined using fair value at the reporting date.

Fair values are determined from market based evidence normally undertaken by professionally qualified valuers.

Revaluation gains and losses are recognised in other comprehensive income unless losses exceed the previously recognised gains or reflect a clear consumption of economic benefits, in which case the excess losses are recognised in profit or loss.

 
2.12

Debtors

Short-term debtors are measured at transaction price, less any impairment.

 
2.13

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours.

In the statement of cash flows, cash and cash equivalents are shown net of bank overdrafts that are repayable on demand and form an integral part of the Company's cash management. 

 
2.14

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.15

Provisions for liabilities

Provisions are recognised when an event has taken place that gives rise to a legal or constructive obligation, a transfer of economic benefits is probable and a reliable estimate can be made.

Provisions are measured as the best estimate of the amount required to settle the obligation, taking into account the related risks and uncertainties.
 
Increases in provisions are generally charged as an expense to profit or loss.

Page 17

 
Medlock FRB Limited
 
 
 
Notes to the Financial Statements
For the year ended 31 December 2025

2.Accounting policies (continued)

 
2.16

Financial instruments

The Company has elected to apply the provisions of Section 11 “Basic Financial Instruments” of FRS 102 to all of its financial instruments.

Basic financial assets

Basic financial assets, which include trade and other debtors, cash and bank balances, are initially measured at their transaction price (adjusted for transaction costs except in the initial measurement of financial assets that are subsequently measured at fair value through profit and loss) and are subsequently carried at their amortised cost using the effective interest method, less any provision for impairment, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

Discounting is omitted where the effect of discounting is immaterial. The Company's cash and cash equivalents, trade and most other debtors due with the operating cycle fall into this category of financial instruments.

Impairment of financial assets

At the end of each reporting period financial assets measured at amortised cost are assessed for objective evidence of impairment. If an asset is impaired the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss. 

Financial assets are impaired when events, subsequent to their initial recognition, indicate the estimated future cash flows derived from the financial asset(s) have been adversely impacted. The impairment loss will be the difference between the current carrying amount and the present value of the future cash flows at the asset(s) original effective interest rate.

If there is a favourable change in relation to the events surrounding the impairment loss then the impairment can be reviewed for possible reversal. The reversal will not cause the current carrying amount to exceed the original carrying amount had the impairment not been recognised. The impairment reversal is recognised in the profit or loss.

Basic financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after the deduction of all its liabilities.

Basic financial liabilities, which include trade and other creditors, bank loans and other loans are initially measured at their transaction price (adjusting for transaction costs except in the initial measurement of financial liabilities that are subsequently measured at fair value through profit and loss). When this constitutes a financing transaction, whereby the debt instrument is measured at the present value of the future payments discounted at a market rate of interest, discounting is omitted where the effect of discounting is immaterial.

Debt instruments are subsequently carried at their amortised cost using the effective interest rate method.

Trade creditors are obligations to pay for goods and services that have been acquired in the ordinary course of business from suppliers. Trade creditors are classified as current liabilities if the payment is due within one year. If not, they represent non-current liabilities. Trade creditors are initially recognised at their transaction price and subsequently are measured at amortised cost using the effective interest method. Discounting is omitted where the effect of discounting is immaterial.
Page 18

 
Medlock FRB Limited
 
 
 
Notes to the Financial Statements
For the year ended 31 December 2025

2.Accounting policies (continued)


2.16
Financial instruments (continued)


Derecognition of financial assets

Financial assets are derecognised when their contractual right to future cash flow expire, or are settled, or when the Company transfers the asset and substantially all the risks and rewards of ownership to another party. If significant risks and rewards of ownership are retained after the transfer to another party, then the Company will continue to recognise the value of the portion of the risks and rewards retained.

Derecognition of financial liabilities

Financial liabilities are derecognised when the Company's contractual obligations expire or are discharged or cancelled.

 
2.17

Employee ownership trust

Investments in the Company's own shares which are held for the benefit of the beneficiaries of the Medlock FRB Employee Ownership Trust are shown as a deduction from shareholder's funds in a separate reserve.


3.


Judgments in applying accounting policies and key sources of estimation uncertainty

Management discussed with the directors the development, selection and disclosure of the Company's critical accounting policies and estimates and the application of these policies and estimates. The key sources of estimation, uncertainty and critical accounting judgements in applying the company's policies are discussed below.

The Company's revenue recognition and margin recognition policies, which are set out in note 2.2, are central to how the Company values the work it has carried out in each financial year. These policies require forecasts to be made of the outcomes of long-term construction contracts. Amounts recoverable on long term contracts included in debtors totalled £5,074,264 
(2024: £7,503,308).


4.


Turnover

An analysis of turnover by class of business is as follows:


2025
2024
£
£

Contract fit out, refurbishment, build and manufactured joinery
40,590,009
45,756,144


All turnover arose within the United Kingdom.

Page 19

 
Medlock FRB Limited
 
 
 
Notes to the Financial Statements
For the year ended 31 December 2025

5.


Other operating income

2025
2024
£
£

Central service fees receivable
16,667
100,000

Government grants receivable
527,525
-

544,192
100,000



6.


Operating profit

The operating profit is stated after charging:

2025
2024
£
£

Operating lease rentals - land and building
30,000
29,333

Operating lease rentals - other
139,134
108,656

Depreciation of tangible fixed assets
50,568
54,918


7.


Auditors' remuneration

During the year, the Company obtained the following services from the Company's auditors:


2025
2024
£
£

Fees payable to the Company's auditors for the audit of the Company's financial statements
15,800
15,275

Fees payable to the Company's auditors for taxation compliance services
2,150
1,300

Fees payable to the Company's auditors for all other services
3,950
12,375
Page 20

 
Medlock FRB Limited
 
 
 
Notes to the Financial Statements
For the year ended 31 December 2025

8.


Employees

Staff costs, including directors' remuneration, were as follows:


2025
2024
£
£

Wages and salaries
3,258,013
3,515,419

Social security costs
430,363
403,577

Cost of defined contribution scheme
160,373
167,275

3,848,749
4,086,271


The average monthly number of employees, including the directors, during the year was as follows:


        2025
        2024
            No.
            No.







Sales, administrative and operations
64
70


9.


Directors' remuneration

2025
2024
£
£

Directors' emoluments
568,560
543,282

Company contributions to defined contribution pension schemes
72,077
64,417

640,637
607,699


During the year retirement benefits were accruing to 7 directors (2024 -7) in respect of defined contribution pension schemes.

The highest paid director received remuneration of £128,231 (2024 -£106,829).

The value of the Company's contributions paid to a defined contribution pension scheme in respect of the highest paid director amounted to £18,000 (2024 -£19,468).


10.


Interest receivable

2025
2024
£
£


Other interest receivable
555
-

Page 21

 
Medlock FRB Limited
 
 
 
Notes to the Financial Statements
For the year ended 31 December 2025

11.


Interest payable and similar expenses

2025
2024
£
£


Bank interest payable
27,464
36,000

Finance leases and hire purchase contracts
2,608
2,608

30,072
38,608


12.


Taxation


2025
2024
£
£

Corporation tax


Current tax on profits for the year
112,826
193,778

Adjustments in respect of previous periods
(338,880)
(206,595)


Total current tax
(226,054)
(12,817)

Deferred tax


Origination and reversal of timing differences
(10,533)
3,682

Adjustments in respect of previous periods
-
(2,544)

Total deferred tax
(10,533)
1,138


Tax on profit
(236,587)
(11,679)
Page 22

 
Medlock FRB Limited
 
 
 
Notes to the Financial Statements
For the year ended 31 December 2025
 
12.Taxation (continued)


Factors affecting tax charge for the year

The tax assessed for the year is lower than (2024 -lower than) the standard rate of corporation tax in the UK of 25% (2024 -25%). The differences are explained below:

2025
2024
£
£


Profit on ordinary activities before tax
238,168
699,198


Profit on ordinary activities multiplied by standard rate of corporation tax in the UK of 25% (2024 -25%)
59,542
174,800

Effects of:


Expenses not deductible for tax purposes
38,251
18,160

Depreciation on ineligible assets
4,500
4,500

Adjustments to tax charge in respect of prior periods
(338,880)
(209,139)

Total tax charge for the year
(236,587)
(11,679)


Factors that may affect future tax charges

There were no factors that may affect future tax charges.

Page 23

 
Medlock FRB Limited
 
 
 
Notes to the Financial Statements
For the year ended 31 December 2025

13.


Tangible fixed assets


Freehold property
Plant and machinery
Total

£
£
£



Cost or valuation


At 1 January 2025
900,000
477,484
1,377,484


Additions
-
16,155
16,155



At 31 December 2025

900,000
493,639
1,393,639



Depreciation


At 1 January 2025
54,000
350,983
404,983


Charge for the year
18,000
32,568
50,568



At 31 December 2025

72,000
383,551
455,551



Net book value



At 31 December 2025
828,000
110,088
938,088



At 31 December 2024
846,000
126,501
972,501

Cost or valuation at 31 December 2025 is as follows:

Freehold property
£


At cost
377,201
At valuation:

Market value for current use - 16 June 2022
522,799



900,000

The freehold property was valued on 16 June 2022 by Longden & Cook Real Estate, Chartered Surveyors at £900,000 which is considered its fair value. 

If the freehold property had not been included at valuation they would have been included under the historical cost convention as follows:

2025
2024
£
£



Cost
377,201
377,201

Accumulated depreciation
(139,792)
(132,248)

Net book value
237,409
244,953

Page 24

 
Medlock FRB Limited
 
 
 
Notes to the Financial Statements
For the year ended 31 December 2025

14.


Debtors

2025
2024
£
£


Trade debtors
1,706,079
1,218,574

Amounts owed by related parties
-
507,893

Other debtors
145,656
-

Prepayments and accrued income
95,549
128,467

Amounts recoverable on long-term contracts
5,074,264
7,503,308

Government grants receivable
414,699
-

7,436,247
9,358,242



15.


Cash and cash equivalents

2025
2024
£
£

Cash at bank and in hand
3,093,222
1,495,739


Page 25

 
Medlock FRB Limited
 
 
 
Notes to the Financial Statements
For the year ended 31 December 2025

16.


Creditors: Amounts falling due within one year

2025
2024
£
£

Bank loans
57,115
53,964

Trade creditors
7,250,245
6,191,090

Corporation tax
-
193,778

Other taxation and social security
803,739
1,200,117

Obligations under finance lease and hire purchase contracts
9,138
8,231

Other creditors
17,730
16,779

Accruals and deferred income
568,021
1,431,462

8,705,988
9,095,421


Obligations under hire purchase contracts are secured against the assets to which they relate.

Bank loans are secured by a legal charge over the Company's property, and by a debenture creating fixed and floating charges over all the Company’s assets, both present and future.

The Company originally entered into a loan facility of £209,000 in March 2019. The loan was repayable by way of 59 monthly instalments, with a final lump sum repayment due in February 2024. Interest was charged at a rate of 2% per annum above the Bank of England base rate. In May 2024, the outstanding balance of £141,598 was refinanced under a new facility. The new loan is repayable by way of 59 monthly instalments, with a final lump sum payment due in April 2029. Interest is charged at 2.75% per annum above the Bank of England base rate.

The Company entered into another loan facility of £337,000 in August 2022. The loan is repayable over a period of 120 months by way of 119 monthly instalments, with a final lump sum payment due in August 2032. Interest is charged at 3% per annum above the Bank of England base rate.


17.


Creditors: Amounts falling due after more than one year

2025
2024
£
£

Bank loans
297,822
356,828

Net obligations under finance leases and hire purchase contracts
15,612
25,519

313,434
382,347


The aggregate amount of liabilities repayable wholly or in part more than five years after the reporting date is:

2025
2024
£
£


Bank loans repayable by instalments
96,586
127,123

Details regarding bank loans and hire purchase contracts are disclosed in note 16.

Page 26

 
Medlock FRB Limited
 
 
 
Notes to the Financial Statements
For the year ended 31 December 2025

18.


Loans


Analysis of the maturity of loans is given below:


2025
2024
£
£

Amounts falling due within one year

Bank loans
57,115
53,964

Amounts falling due 1-2 years

Bank loans
60,561
57,479

Amounts falling due 2-5 years

Bank loans
140,675
172,226

Amounts falling due after more than 5 years

Bank loans
96,586
127,123

354,937
410,792


Details regarding bank loans are disclosed in note 16.


19.


Hire purchase


Minimum lease payments under hire purchase fall due as follows:

2025
2024
£
£


Within one year
11,608
11,608

Between 1-5 years
20,315
31,923

31,923
43,531


20.


Deferred taxation




2025
2024


£

£






Liability at beginning of year
(24,716)
(23,578)


Charged to profit or loss
10,533
(1,138)



Liability at end of year
(14,183)
(24,716)

Page 27

 
Medlock FRB Limited
 
 
 
Notes to the Financial Statements
For the year ended 31 December 2025
 
20.Deferred taxation (continued)

The provision for deferred taxation is made up as follows:

2025
2024
£
£


Accelerated capital allowances
24,645
28,589

Other timing differences
(10,462)
(3,873)

14,183
24,716


21.


Share capital

2025
2024
£
£
Allotted, called up and fully paid



6,667 (2024 -6,667) Ordinary A shares of £1.00 each
6,667
6,667
6,667 (2024 -6,667) Ordinary B shares of £1.00 each
6,667
6,667
6,667 (2024 -6,667) Ordinary C shares of £1.00 each
6,667
6,667
1,112 (2024 -1,112) Ordinary D shares of £1.00 each
1,112
1,112
1,112 (2024 -1,112) Ordinary E shares of £1.00 each
1,112
1,112

22,225

22,225



22.


Reserves

Non-distributable reserves

A revaluation reserve arose on a revaluation of a property in accordance with UK GAAP.

Profit and loss account

The profit and loss account includes all current and prior period retained profit and losses net of dividends.

Other reserves

Other reserves include contributions made to the Medlock FRB Employee Ownership Trust. 


23.


Pension commitments

The Company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the Company in an independently administered fund. The pension cost charged represents contributions payable by the Company to the fund and amounted to £124,373 (2024 - £129,807). Contributions totalling £16,443 (2024 - £15,492) were payable to the fund at the balance sheet date.

During the year, the company made contributions of £36,000 
(2024 - £37,468) to the directors personal pension funds. Contributions totalling £Nil (2024 - £Nil) were payable to the fund at the balance sheet date.

Page 28

 
Medlock FRB Limited
 
 
 
Notes to the Financial Statements
For the year ended 31 December 2025

24.


Commitments under operating leases

At 31 December 2025 the Company had future minimum lease payments due under non-cancellable operating leases for each of the following periods:

2025
2024
£
£

Land and buildings


Not later than 1 year
30,000
30,000

Later than 1 year and not later than 5 years
12,500
42,500

42,500
72,500

2025
2024

£
£

Other


Not later than 1 year
139,720
130,760

Later than 1 year and not later than 5 years
90,694
187,048

230,414
317,808


25.


Related party transactions

A company manages the individual SIPPs of two directors, which owns the property from which Medlock FRB Limited trades. The company charged Medlock FRB Limited £30,000 (2024 - £29,333).

At the year end, a company related to Medlock FRB Limited through common control credited £61,630 
(2024 - charged £60,480) to Medlock FRB Limited and was charged £88,152 (2024 - £509,780) by Medlock FRB Limited. The company owes £Nil (2024 - £507,893) to Medlock FRB Limited at the balance sheet date, with £100,000 (2024 - £Nil) of amounts owed to Medlock FRB Limited in relation to financial support written off upon dissolution of the company.

Another company related to Medlock FRB Limited through common control charged £50,000 
(2024 - £Nil) to Medlock FRB and was charged £4,384 (2024 - £Nil). There was no outstanding balance at the balance sheet date (2024 - £Nil).

Key management personnel remuneration totalled £640,637 
(2024 - £607,699). The directors consider there are no further key management in addition to the directors.


26.


Controlling party

The Company is wholly owned by the Medlock FRB Employee Ownership Trust.
 
Page 29